Review paper

Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer

Volume: 30, Issue: 4, Pages: 343 - 350
Published: Mar 9, 2021
Abstract
Introduction: The prognosis of patients with advanced biliary tract cancer (BTC) remains dismal, with a 5-year overall survival rate of less than 10%. Although immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of several hematological and solid tumors, controversial results have been reported in BTC. In this setting, the anti-PD-L1 inhibitor durvalumab is currently under investigation in several clinical trials as...
Paper Details
Title
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Published Date
Mar 9, 2021
Volume
30
Issue
4
Pages
343 - 350
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.